Cytovation AS
🇳🇴Norway
- Country
- 🇳🇴Norway
- Ownership
- Holding
- Established
- 2001-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.cytovation.com
Clinical Trials
4
Active:2
Completed:2
Trial Phases
1 Phases
Phase 1:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (100.0%)A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers
Phase 1
Active, not recruiting
- Conditions
- Advanced Head and Neck Squamous Cell CarcinomaAdvanced Breast CancerAdvanced Melanoma
- Interventions
- First Posted Date
- 2022-05-20
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Cytovation AS
- Target Recruit Count
- 90
- Registration Number
- NCT05383170
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸City Of Hope, Duarte, California, United States
🇺🇸Henry Ford Health System, Detroit, Michigan, United States
CyPep-1 Injections in Cancer Inducing Lymphocyte Infiltrate Accumulations
Phase 1
Completed
- Conditions
- Advanced Solid Tumor Malignancy
- Interventions
- First Posted Date
- 2020-02-07
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Cytovation AS
- Target Recruit Count
- 60
- Registration Number
- NCT04260529
- Locations
- 🇫🇷
Institue Curie, Paris, France
🇫🇷Institute Gustave Roussy, Villejuif, France
🇳🇱NKI/AvL, Amsterdam, Netherlands
News
No news found